Market Research Report
Global Liver Diseases Therapeutics Market 2015-2019
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||341174|
|Published||Content info||95 Pages
|Global Liver Diseases Therapeutics Market 2015-2019|
|Published: September 30, 2015||Content info: 95 Pages||
Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.
Technavio's analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.
This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.
Based on disease indication, the market is segmented as follows:
This report includes a discussion of the market in the following three regions:
Technavio's report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.